Carotuximab
- CAS No.
- 1268714-50-6
- Chemical Name:
- Carotuximab
- Synonyms
- Carotuximab;DE-122|||TRC105;Carotuximab (anti-CD105);Research Grade Carotuximab;Research Grade Carotuximab (DHD26501)
- CBNumber:
- CB48080981
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | YB2EWE6139 |
| NCI Drug Dictionary | carotuximab |
Carotuximab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628003 | Carotuximab ≥95.0% | 1268714-50-6 | 1mg | $217 | 2026-06-04 | Buy |
| ChemScene | CS-0628003 | Carotuximab ≥95.0% | 1268714-50-6 | 5mg | $650 | 2026-06-04 | Buy |
| ChemScene | CS-0628003 | Carotuximab ≥95.0% | 1268714-50-6 | 10mg | $1040 | 2026-06-04 | Buy |
| aablocks | AA029Z23 | Carotuximab ≥95%(SDS-PAGE&SEC-HPLC) | 1268714-50-6 | 1mg | $420 | 2026-06-02 | Buy |
| aablocks | AA029Z23 | Carotuximab ≥95%(SDS-PAGE&SEC-HPLC) | 1268714-50-6 | 5mg | $1230 | 2026-06-02 | Buy |
Carotuximab Chemical Properties, Uses, Production
Uses
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].
in vivo
Carotuximab (TRC105; 2 mg/kg; i.v; every 3 days; for 8 weeks) along with Decitabine results in a more durable anti-leukemic effect in acute myeloid leukemia (AML) xenografts. And also enhances reactive oxygen species (ROS) activity[2].
| Animal Model: | Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] |
| Dosage: | 2 mg/kg |
| Administration: | i.v; every 3 days; for 8 weeks |
| Result: | Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts. |
References
[1] Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. DOI:10.3389/fmed.2022.845918
[2] June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242. DOI:10.1016/j.heliyon.2020.e05242
Carotuximab Preparation Products And Raw materials
Raw materials
Preparation Products
Carotuximab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
View Latest Price from Carotuximab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Carotuximab
1268714-50-6
|
$129.00-635.00 | SDS-PAGE:95% SEC-HPLC:95% | 10g | TargetMol Chemicals Inc. |
-
- Carotuximab
1268714-50-6
- $129.00-635.00
- SDS-PAGE:95% SEC-HPLC:95%
- TargetMol Chemicals Inc.
